The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.
Stakeholders increasingly highlight the need for better, more standardized tools to validate and compare liquid biopsy tests, and commercial firms have responded.
The technology is based on helitrons, a type of eukaryotic transposon that can incorporate multiple copies of a DNA sequence into a genome.
The deal covers Atum's custom vectors and Horizon's CHO Source biomanufacturing platform.
The firm has secured rights to use CRISPR in cell lines for biomanufacturing and will work with Solentim to increase editing throughput while decreasing costs.
The partnership aims to improve cancer molecular profiling by combining Horizon's HDx reference standards with Sophia's artificial intelligence solution.
Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for the monitoring of transplanted organ rejection.
Horizon Discovery, Desktop Genetics, and Vectalys will work together to create fully-licensed, customizable kits for CRISPR/Cas9-based genetic screening.
Revenues increased on gains in product sales, which helped offset a decline in molecular screening revenues.
Cell line engineers from Horizon Genomics said a method to make or undo fusion oncogenes in cell lines could help create reference standards for cancer diagnostics.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.